Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes

E. M. Heintjes; T. L. Thomsen; F. J. Penning-van Beest; T. E. Christensen; R. M. Herings

doi:https://doi.org/10.1007/s12325-010-0020-y

Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes

E. M. Heintjes, T. L. Thomsen, F. J. Penning-van Beest, T. E. Christensen, R. M. Herings

Epidemiology and Data Science (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

INTRODUCTION: The objective was to compare glycemic control, insulin utilization, and body weight in patients with type 2 diabetes (T2D) initiated on insulin detemir (IDet) or insulin glargine (IGlar) in a real-life setting in the Netherlands. METHODS: Insulin-naive patients with T2D, starting treatment with IDet or IGlar between January 1, 2004 and June 30, 2008, were selected from the PHARMO data network. Glycemic control (hemoglobin A1c [HbA1c]), target rates (HbA1c

Original language	English
Pages (from-to)	211-222
Number of pages	12
Journal	Advances in therapy
Volume	27
Issue number	4
DOIs	https://doi.org/10.1007/s12325-010-0020-y
Publication status	Published - 2010

Keywords

Aged Body Weight/drug effects Cohort Studies Delayed-Action Preparations Diabetes Mellitus, Type 2/*drug therapy Drug Utilization Female Glycated Hemoglobin A/analogs & derivatives/analysis Humans Hypoglycemic Agents/administration & dosage/*therapeutic use Insulin/administration & dosage/*analogs & derivatives/therapeutic use Insulin Detemir Insulin Glargine Insulin, Long-Acting Insurance Claim Review Male Middle Aged Retrospective Studies

Access to Document

https://doi.org/10.1007/s12325-010-0020-y

https://www.ncbi.nlm.nih.gov/pubmed/20449697

Cite this

@article{0c9a7a67f92c4c858dda9ad6f6d098d9,

title = "Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes",

abstract = "INTRODUCTION: The objective was to compare glycemic control, insulin utilization, and body weight in patients with type 2 diabetes (T2D) initiated on insulin detemir (IDet) or insulin glargine (IGlar) in a real-life setting in the Netherlands. METHODS: Insulin-naive patients with T2D, starting treatment with IDet or IGlar between January 1, 2004 and June 30, 2008, were selected from the PHARMO data network. Glycemic control (hemoglobin A1c [HbA1c]), target rates (HbA1c",

keywords = "Aged Body Weight/drug effects Cohort Studies Delayed-Action Preparations Diabetes Mellitus, Type 2/*drug therapy Drug Utilization Female Glycated Hemoglobin A/analogs & derivatives/analysis Humans Hypoglycemic Agents/administration & dosage/*therapeutic use Insulin/administration & dosage/*analogs & derivatives/therapeutic use Insulin Detemir Insulin Glargine Insulin, Long-Acting Insurance Claim Review Male Middle Aged Retrospective Studies",

author = "Heintjes, {E. M.} and Thomsen, {T. L.} and {Penning-van Beest}, {F. J.} and Christensen, {T. E.} and Herings, {R. M.}",

note = "Heintjes, Edith M Thomsen, Trine L Penning-van Beest, Fernie J A Christensen, Torsten E Herings, Ron M C eng Research Support, Non-U.S. Gov't Adv Ther. 2010 Apr;27(4):211-22. doi: 10.1007/s12325-010-0020-y. Epub 2010 May 4.",

year = "2010",

doi = "https://doi.org/10.1007/s12325-010-0020-y",

language = "English",

volume = "27",

pages = "211--222",

journal = "Advances in therapy",

issn = "1865-8652",

publisher = "Health Communications Inc.",

number = "4",

}

TY - JOUR

T1 - Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes

AU - Heintjes, E. M.

AU - Thomsen, T. L.

AU - Penning-van Beest, F. J.

AU - Christensen, T. E.

AU - Herings, R. M.

N1 - Heintjes, Edith M Thomsen, Trine L Penning-van Beest, Fernie J A Christensen, Torsten E Herings, Ron M C eng Research Support, Non-U.S. Gov't Adv Ther. 2010 Apr;27(4):211-22. doi: 10.1007/s12325-010-0020-y. Epub 2010 May 4.

PY - 2010

Y1 - 2010

N2 - INTRODUCTION: The objective was to compare glycemic control, insulin utilization, and body weight in patients with type 2 diabetes (T2D) initiated on insulin detemir (IDet) or insulin glargine (IGlar) in a real-life setting in the Netherlands. METHODS: Insulin-naive patients with T2D, starting treatment with IDet or IGlar between January 1, 2004 and June 30, 2008, were selected from the PHARMO data network. Glycemic control (hemoglobin A1c [HbA1c]), target rates (HbA1c

AB - INTRODUCTION: The objective was to compare glycemic control, insulin utilization, and body weight in patients with type 2 diabetes (T2D) initiated on insulin detemir (IDet) or insulin glargine (IGlar) in a real-life setting in the Netherlands. METHODS: Insulin-naive patients with T2D, starting treatment with IDet or IGlar between January 1, 2004 and June 30, 2008, were selected from the PHARMO data network. Glycemic control (hemoglobin A1c [HbA1c]), target rates (HbA1c

KW - Aged Body Weight/drug effects Cohort Studies Delayed-Action Preparations Diabetes Mellitus, Type 2/drug therapy Drug Utilization Female Glycated Hemoglobin A/analogs & derivatives/analysis Humans Hypoglycemic Agents/administration & dosage/therapeutic use

U2 - https://doi.org/10.1007/s12325-010-0020-y

DO - https://doi.org/10.1007/s12325-010-0020-y

M3 - Article

SN - 1865-8652

VL - 27

SP - 211

EP - 222

JO - Advances in therapy

JF - Advances in therapy

IS - 4

ER -